Sino Biopharmaceutical edged down today, closing at HKD 5.51, declining roughly 0.9%, as profit-taking emerged following recent strength. The company has secured a significant milestone through a collaboration with Boehringer Ingelheim valued at up to USD 7.4 billion for oncology drug development and commercialization, backed by analyst support including CICC's maintained Buy rating and UOB Kay Hian's raised target price to HKD 7.5. Latest Q2 earnings show operating revenue of HKD 11.23 billion, up 16.62% year-over-year, with operating profit surging 104.47% year-over-year and net profit reaching HKD 1.98 billion, up 6.84% year-over-year, reflecting a net margin of 17.66% and ROE of 21.09%. However, the current price remains 26% below the 52-week high of HKD 7.48, down 13.36% year-to-date, with a P/E multiple of 37.4x reflecting elevated market expectations for future growth.